BRIEF-Intellipharmaceutics says Rexista results indicate no food effect

Tue Jul 5, 2016 7:53am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 5 (Reuters) - Intellipharmaceutics International Inc :

* Intellipharmaceutics reports update on Rexista XR: FDA grants waiver of NDA filing fee, and topline pharmacokinetics results indicate no food effect

* FDA has completed its review of our request and has granted a waiver of $1,187,100 application fee for Rexista XR

* Food effect study showed that Rexista XR can be administered with or without a meal

* Company plans to file NDA for Rexista XR in August of 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)